Backgrounds::Cardiovascular disease(CVD)remains the leading cause of deaths nationwide.However,little is understood about its temporal trend and corresponding influence on longevity improvements.We aimed to describe t...Backgrounds::Cardiovascular disease(CVD)remains the leading cause of deaths nationwide.However,little is understood about its temporal trend and corresponding influence on longevity improvements.We aimed to describe the updated tendency in CVD mortality and to quantify its impact on life expectancy(LE)increase in China.Methods::All-cause mortality rates were calculated with population sizes from the National Bureau of Statistics and death counts from the National Health Commission.We estimated CVD mortality rates by allocating age-and sex-based mortality envelopes to each CVD subtype based on its proportion derived from the Disease Surveillance Points system.The probability of CVD premature deaths and LE were calculated with life tables and we adopted Arriaga’s method to quantitate age-and cause-specific contributions to LE gains.Results::During 2013 to 2018,the age-standardized mortality rate of CVD decreased from 289.69(95%confidence interval[CI]:289.03,290.35)/100,000 to 272.37(95%CI:271.81,272.94)/100,000,along with a decline in probability of CVD premature deaths from 9.05%(95%CI:9.02%,9.09%)to 8.13%(95%CI:8.10%,8.16%).The gap in CVD mortality across sexes expanded with more remarkable declines in females,especially for those aged 15 to 64 years.Among major subtypes,the probability of premature deaths from hemorrhage stroke declined fastest,while improvements of ischemic stroke and ischemic heart disease were limited,and there was an increase in stroke sequelae.LE in China reached 77.04(95%CI:76.96,77.12)years in 2018 with an increase of 1.38 years from 2013.Of the total LE gains,21.15%(0.29 years)were attributed to reductions of CVD mortality in the overall population,mostly driven by those aged>65 years.Conclusions::The general process in reducing CVD mortality has contributed to longevity improvements in China.More attention should be paid to prevention and control of atherosclerotic CVD and stroke sequelae,especially for the elderly.Working-age males also deserve additional attention due to inadequate improvements.展开更多
BACKGROUNDNon-alcoholic fatty liver disease (NAFLD) is a systemic disease with bidirectionalrelationships with cardiovascular disease (CVD). Non-alcoholic steatohepatitis(NASH) is a more severe subtype of NAFLD. Patie...BACKGROUNDNon-alcoholic fatty liver disease (NAFLD) is a systemic disease with bidirectionalrelationships with cardiovascular disease (CVD). Non-alcoholic steatohepatitis(NASH) is a more severe subtype of NAFLD. Patients with NASH exhibit moreintra and extrahepatic inflammation, procoagulant imbalances andproatherogenic lipid profiles. Whether NASH increases the risk of ischemic heartdisease is currently unclear.AIMTo investigate the relationship between acute myocardial infarction (MI) andNASH in a large cohort of subjects in the United States.METHODSWe reviewed data from a large commercial database (Explorys IBM) thataggregates electronic health records from 26 large nationwide healthcare systems.Using systemized nomenclature of clinical medical terms (SNOMED CT), weidentified adult with the diagnosis of NASH from 1999-2019. We includedpatients with the diagnosis of acute MI from 2018-2019. Comorbidities known tobe associated with NASH and MI such as obesity, diabetes mellitus,hyperlipidemia, smoking, male gender, and hypertension were collected.Univariable and multivariable analyses were performed to investigate whetherNASH is independently associated with the risk of MI.RESULTSOut of 55099280 patients, 43170 were diagnosed with NASH (0.08%) and 107000(0.194%) had a MI within 2018-2019. After adjusting for traditional risk factors,NASH conferred greater odds of MI odds ratio (OR) 1.5 [95% confidence interval(CI): 1.40-1.62]. Hyperlipidemia had the strongest association with MI OR 8.39(95%CI: 8.21-8.58) followed by hypertension OR 3.11 (95%CI: 3.05-3.17) andsmoking OR 2.83 (95%CI: 2.79-2.87). NASH had a similar association with MI asthe following traditional risk factors like age above 65 years OR 1.47 (95%CI: 1.45-1.49), male gender OR 1.53 (95%CI: 1.51-1.55) diabetes mellitus OR 1.89 (95%CI:1.86-1.91).CONCLUSIONMI appears to be a prevalent disease in NASH. Patients with NASH may needearly identification and aggressive cardiovascular risk modification.展开更多
近十年来,心血管磁共振(cardiovascular magnetic resonance,CMR)成像技术作为一种无创性评估心脏结构与功能的“金标准”,已在国内心血管疾病临床诊疗领域发挥了重要作用。伴随着组织学特征成像、特征追踪技术、扩散加权成像、影像组...近十年来,心血管磁共振(cardiovascular magnetic resonance,CMR)成像技术作为一种无创性评估心脏结构与功能的“金标准”,已在国内心血管疾病临床诊疗领域发挥了重要作用。伴随着组织学特征成像、特征追踪技术、扩散加权成像、影像组学和人工智能等新技术的出现,CMR为心血管系统疾病精准诊疗提供了新的机遇。国内许多医院已经采用CMR对缺血性心脏病、非缺血性心脏病、大血管疾病等进行精准评估,取得了系列研究成果。相信未来CMR将在组织学特征成像、影像组学和人工智能、分子成像以及疾病的早期诊断、危险分层、预后评估等方面取得更大的研究成果。本文对十年来国内CMR领域临床和科研进展进行总结,并展望未来发展方向,以期为CMR技术研究与临床研究提供相关参考。展开更多
文摘目的评价吲哚布芬在治疗动脉硬化所致的缺血性心血管病变中的有效性与安全性。方法以“吲哚布芬”和“indobufen”作为关键词设定一定策略计算机检索The Cochrane Library、PubMed、EMbase、ClinicalTrial.gov、中国知网和万方数据库(时间由建库至2021年4月)的数据。按纳入与排除标准筛选文献、提取资料并评价纳入研究的方法学质量后,采用Rev Man 5.3软件进行Meta分析。结果共29项随机对照试验纳入分析,包括3329例患者,其中观察组1674例、对照组1655例。有效性结局显示,在不稳定型心绞痛治疗的总有效率方面吲哚布芬单药显著优于阿司匹林(风险比=1.29,95%置信区间:1.21~1.38,P<0.00001);吲哚布芬联合氯吡格雷治疗急性冠状动脉综合征的总有效率显著优于阿司匹林联合氯吡格雷(风险比=1.19,95%置信区间:1.03~1.36,P=0.01);吲哚布芬联合替格瑞洛在冠心病(冠状动脉粥样硬化性心脏病)经皮冠状动脉介入术后总心血管事件发生率显著低于阿司匹林联合替格瑞洛(I^(2)=0,风险比=0.25,95%置信区间:0.10~0.65,P<0.01);吲哚布芬治疗冠心病冠状动脉旁路移植术后患者移植血管闭塞事件的短期发生率显著低于阿司匹林联合双嘧达莫(风险比=0.26,95%置信区间:0.10~0.65,P<0.01)。安全性结果显示,吲哚布芬联合氯吡格雷治疗不稳定型心绞痛导致出血事件和胃肠道反应的发生率显著低于阿司匹林联合氯吡格雷;吲哚布芬联合氯吡格雷在冠心病经皮冠状动脉介入术后轻微出血事件和胃肠道反应的发生率显著低于阿司匹林联合氯吡格雷。结论吲哚布芬在治疗动脉硬化所致的缺血性心血管病变方面已积累了一定的循证证据,吲哚布芬单药或与氯吡格雷联合使用在有效性和安全性方面均显示出较好的优势。
基金This study was supported by grants from the Chinese Academyof MedicalSciences(CAMS)Innovation Fund for Medical Sciences(No.2021-I2M-1-010,No.2017-I2M-1-004)the National Natural Science Foundation of China(No.12126602,No.82030102)the National Key R&D Program of China(No.2017YFC0211700).
文摘Backgrounds::Cardiovascular disease(CVD)remains the leading cause of deaths nationwide.However,little is understood about its temporal trend and corresponding influence on longevity improvements.We aimed to describe the updated tendency in CVD mortality and to quantify its impact on life expectancy(LE)increase in China.Methods::All-cause mortality rates were calculated with population sizes from the National Bureau of Statistics and death counts from the National Health Commission.We estimated CVD mortality rates by allocating age-and sex-based mortality envelopes to each CVD subtype based on its proportion derived from the Disease Surveillance Points system.The probability of CVD premature deaths and LE were calculated with life tables and we adopted Arriaga’s method to quantitate age-and cause-specific contributions to LE gains.Results::During 2013 to 2018,the age-standardized mortality rate of CVD decreased from 289.69(95%confidence interval[CI]:289.03,290.35)/100,000 to 272.37(95%CI:271.81,272.94)/100,000,along with a decline in probability of CVD premature deaths from 9.05%(95%CI:9.02%,9.09%)to 8.13%(95%CI:8.10%,8.16%).The gap in CVD mortality across sexes expanded with more remarkable declines in females,especially for those aged 15 to 64 years.Among major subtypes,the probability of premature deaths from hemorrhage stroke declined fastest,while improvements of ischemic stroke and ischemic heart disease were limited,and there was an increase in stroke sequelae.LE in China reached 77.04(95%CI:76.96,77.12)years in 2018 with an increase of 1.38 years from 2013.Of the total LE gains,21.15%(0.29 years)were attributed to reductions of CVD mortality in the overall population,mostly driven by those aged>65 years.Conclusions::The general process in reducing CVD mortality has contributed to longevity improvements in China.More attention should be paid to prevention and control of atherosclerotic CVD and stroke sequelae,especially for the elderly.Working-age males also deserve additional attention due to inadequate improvements.
基金We gratefully acknowledge Dr.Joseph Sudano for ensuring the data analysis is appropriate for this research.
文摘BACKGROUNDNon-alcoholic fatty liver disease (NAFLD) is a systemic disease with bidirectionalrelationships with cardiovascular disease (CVD). Non-alcoholic steatohepatitis(NASH) is a more severe subtype of NAFLD. Patients with NASH exhibit moreintra and extrahepatic inflammation, procoagulant imbalances andproatherogenic lipid profiles. Whether NASH increases the risk of ischemic heartdisease is currently unclear.AIMTo investigate the relationship between acute myocardial infarction (MI) andNASH in a large cohort of subjects in the United States.METHODSWe reviewed data from a large commercial database (Explorys IBM) thataggregates electronic health records from 26 large nationwide healthcare systems.Using systemized nomenclature of clinical medical terms (SNOMED CT), weidentified adult with the diagnosis of NASH from 1999-2019. We includedpatients with the diagnosis of acute MI from 2018-2019. Comorbidities known tobe associated with NASH and MI such as obesity, diabetes mellitus,hyperlipidemia, smoking, male gender, and hypertension were collected.Univariable and multivariable analyses were performed to investigate whetherNASH is independently associated with the risk of MI.RESULTSOut of 55099280 patients, 43170 were diagnosed with NASH (0.08%) and 107000(0.194%) had a MI within 2018-2019. After adjusting for traditional risk factors,NASH conferred greater odds of MI odds ratio (OR) 1.5 [95% confidence interval(CI): 1.40-1.62]. Hyperlipidemia had the strongest association with MI OR 8.39(95%CI: 8.21-8.58) followed by hypertension OR 3.11 (95%CI: 3.05-3.17) andsmoking OR 2.83 (95%CI: 2.79-2.87). NASH had a similar association with MI asthe following traditional risk factors like age above 65 years OR 1.47 (95%CI: 1.45-1.49), male gender OR 1.53 (95%CI: 1.51-1.55) diabetes mellitus OR 1.89 (95%CI:1.86-1.91).CONCLUSIONMI appears to be a prevalent disease in NASH. Patients with NASH may needearly identification and aggressive cardiovascular risk modification.
文摘近十年来,心血管磁共振(cardiovascular magnetic resonance,CMR)成像技术作为一种无创性评估心脏结构与功能的“金标准”,已在国内心血管疾病临床诊疗领域发挥了重要作用。伴随着组织学特征成像、特征追踪技术、扩散加权成像、影像组学和人工智能等新技术的出现,CMR为心血管系统疾病精准诊疗提供了新的机遇。国内许多医院已经采用CMR对缺血性心脏病、非缺血性心脏病、大血管疾病等进行精准评估,取得了系列研究成果。相信未来CMR将在组织学特征成像、影像组学和人工智能、分子成像以及疾病的早期诊断、危险分层、预后评估等方面取得更大的研究成果。本文对十年来国内CMR领域临床和科研进展进行总结,并展望未来发展方向,以期为CMR技术研究与临床研究提供相关参考。
